Drug Profile
Research programme: 5-lipoxygenase inhibitors - Panmira Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amira Pharmaceuticals
- Developer Panmira Pharmaceuticals
- Class
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA
- 07 Sep 2011 Amira Pharmaceuticals has been acquired by Bristol-Myers Squibb